S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

COLL Collegium Pharmaceutical Inc

29.96

-0.45 (-1.48%)

Nov 22 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/13/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jared Cook, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Thomas B Smith

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Collegium Pharmaceutical Charts.

Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Collegium Pharmaceutical Charts.

Collegium Pharmaceutical Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 14 November 2024 (1 week ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Thursday 14 November 2024 (1 week ago) • Edgar (US Regulatory)

Collegium to Participate in Upcoming Investor Conferences
Tuesday 12 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Collegium Reports Record Third Quarter 2024 Financial Results
Thursday 7 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 7 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Collegium Appoints Vikram Karnani as Chief Executive Officer
Thursday 7 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
Thursday 24 October 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 13 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 13 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 September 2024 (3 months ago) • Edgar (US Regulatory)

More Collegium Pharmaceutical Inc News Articles

Global Developments (PK)

Baron Capital Enterprise (CE)

Anavex Life Sciences

Kraig Biocraft Laborator... (QB)

Northwest Biotherapeutics (QB)

Bioelectronics (PK)

Rennova Health (CE)

Lightwave Logic

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions